Cargando…

NO and hepatocellular cancer

NO has broad and sometimes dichotomous roles in cancer. The effects of NO in tumours depend on the type and localization of NOS isoforms, concentration and duration of NO exposure, and cellular sensitivity to NO. Hepatocellular carcinoma (HCC) is a common and lethal disease for which no effective th...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Ronghua, Geller, David A., Wink, David A., Cheng, Bin, Billiar, Timothy R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7707086/
https://www.ncbi.nlm.nih.gov/pubmed/31423564
http://dx.doi.org/10.1111/bph.14838
_version_ 1783617276220538880
author Wang, Ronghua
Geller, David A.
Wink, David A.
Cheng, Bin
Billiar, Timothy R.
author_facet Wang, Ronghua
Geller, David A.
Wink, David A.
Cheng, Bin
Billiar, Timothy R.
author_sort Wang, Ronghua
collection PubMed
description NO has broad and sometimes dichotomous roles in cancer. The effects of NO in tumours depend on the type and localization of NOS isoforms, concentration and duration of NO exposure, and cellular sensitivity to NO. Hepatocellular carcinoma (HCC) is a common and lethal disease for which no effective therapy other than surgical resection exists. Over two decades of research has yielded evidence that NO generated by the inducible NOS (iNOS or NOS2) contributes to HCC progression in at least a subset of patients with HCC. The co‐expression of iNOS with COX‐2 may portend a particularly aggressive cancer phenotype in HCC and at the same time reveal an opportunity for pharmacological intervention. In this review, we focus on what is known about the influence of NO in HCC neoplastic transformation, proliferation and apoptosis, angiogenesis, invasion, and metastasis, cancer stem cells, and the host immune response against the tumour. We discuss the implications of recent findings for targeting the NO pathways in HCC.
format Online
Article
Text
id pubmed-7707086
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-77070862020-12-09 NO and hepatocellular cancer Wang, Ronghua Geller, David A. Wink, David A. Cheng, Bin Billiar, Timothy R. Br J Pharmacol TARGETING THE NITRIC OXIDE (NO)‐cGMP PATHWAY: THERAPEUTIC OPPORTUNITIES IN THE 21ST CENTURY NO has broad and sometimes dichotomous roles in cancer. The effects of NO in tumours depend on the type and localization of NOS isoforms, concentration and duration of NO exposure, and cellular sensitivity to NO. Hepatocellular carcinoma (HCC) is a common and lethal disease for which no effective therapy other than surgical resection exists. Over two decades of research has yielded evidence that NO generated by the inducible NOS (iNOS or NOS2) contributes to HCC progression in at least a subset of patients with HCC. The co‐expression of iNOS with COX‐2 may portend a particularly aggressive cancer phenotype in HCC and at the same time reveal an opportunity for pharmacological intervention. In this review, we focus on what is known about the influence of NO in HCC neoplastic transformation, proliferation and apoptosis, angiogenesis, invasion, and metastasis, cancer stem cells, and the host immune response against the tumour. We discuss the implications of recent findings for targeting the NO pathways in HCC. John Wiley and Sons Inc. 2019-12-11 2020-12 /pmc/articles/PMC7707086/ /pubmed/31423564 http://dx.doi.org/10.1111/bph.14838 Text en © 2019 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle TARGETING THE NITRIC OXIDE (NO)‐cGMP PATHWAY: THERAPEUTIC OPPORTUNITIES IN THE 21ST CENTURY
Wang, Ronghua
Geller, David A.
Wink, David A.
Cheng, Bin
Billiar, Timothy R.
NO and hepatocellular cancer
title NO and hepatocellular cancer
title_full NO and hepatocellular cancer
title_fullStr NO and hepatocellular cancer
title_full_unstemmed NO and hepatocellular cancer
title_short NO and hepatocellular cancer
title_sort no and hepatocellular cancer
topic TARGETING THE NITRIC OXIDE (NO)‐cGMP PATHWAY: THERAPEUTIC OPPORTUNITIES IN THE 21ST CENTURY
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7707086/
https://www.ncbi.nlm.nih.gov/pubmed/31423564
http://dx.doi.org/10.1111/bph.14838
work_keys_str_mv AT wangronghua noandhepatocellularcancer
AT gellerdavida noandhepatocellularcancer
AT winkdavida noandhepatocellularcancer
AT chengbin noandhepatocellularcancer
AT billiartimothyr noandhepatocellularcancer